LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

The market needs to reclaim and sustain above the 20-day EMA to witness a further northward journey in the upcoming sessions.

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Shares of Sun Pharmaceutical Industries climbed nearly 3 per cent on Tuesday after the firm said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for ...

With the stock's last traded price at Rs 1,728.30, Sun Pharmaceutical Industries demonstrates strong financial metrics and active corporate actions, contributing to its market performance.

Shares of firms like HDFC Life, HDB Financial, HCL Tech, RVNL, Sun Pharma, and others will be in focus on Tuesday's trade ...

Stock recommendations today include HCLTech, Ola Electric, Kalyan Jewellers, and Sun Pharma as analysts review June quarter ...

From the Sensex firms, Sun Pharma, Bajaj Finserv, Trent, Tata Motors and Mahindra & Mahindra were among the gainers, with Sun ...

A Sun Pharmaceutical plant in India that has been repeatedly cited by the FDA for serious quality control issues failed another inspection last month.

Sun Pharmaceutical Industries Limited announced Leqselvi (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the US. Leqselvi is ...